StreetAlpha.app
Home › Stocks › CABA

Cabaletta Bio, Inc. (CABA)

Healthcare
$0.94
▼ −7.32%
LAST CLOSE · NOV 20

Cabaletta Bio develops engineered T cell therapies for autoimmune diseases, with its lead candidate in clinical trials. It last closed at $0.94 on Nov 20, down 7.32% on the day. The next earnings report for CABA is expected around Mon, Mar 22, 2027. For the quarter ended Sep 2026, CABA reported EPS of -$0.28. Over its last 8 reports the stock moved an average of 13.0% the session after earnings. Over the last 12 months CABA insiders bought $296K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is CABA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CABA.

Key Stats

Last 12 months
Results
Net income
−$189.5M
EPS (diluted)
−$1.33
Free cash flow
−$162.5M
Valuation
Market cap
$201.9M
215.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$299.4M
At Sep 30
Shareholder equity
$283.9M
Shares outstanding
215.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$46.3M−$46.3MFY2021FY2022: −$53.0M−$53.0MFY2022FY2023: −$67.7M−$67.7MFY2023FY2024: −$115.9M−$115.9MFY2024FY2025: −$167.9M−$167.9MFY2025

From CABA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 22
Estimated date · Time not announced
Reported EPS
-$0.28
Quarter ended Sep 2026
Year ago EPS
-$0.44
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.65Dec '24Mar 2025: -$0.71Mar '25Jun 2025: -$0.73Jun '25Sep 2025: -$0.44Sep '25Dec 2025: -$0.35Dec '25Mar 2026: -$0.39Mar '26Jun 2026: -$0.34Jun '26Sep 2026: -$0.28Sep '26Latest -$0.28
Revenue by quarter
Not enough quarters on file yet.
How CABA moved after its last 8 reports
Average move the session after a report ±13.0%
Nov 5, 2026Time not announced−9.9%
Aug 13, 2026Time not announced−4.9%
May 4, 2026Time not announced+30.3%
Mar 23, 2026Time not announced−4.1%
Nov 10, 2025Time not announced−4.7%
Aug 7, 2025Time not announced0.0%
May 15, 2025Time not announced+39.2%
Mar 31, 2025Time not announced−10.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CABAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CABA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CABA

Technical Analysis

CABA · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 41% below its 20 day and 85% below its 50 day average. It is 194% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 52 week low at $0.93, and the nearest resistance the Pivot at $0.97.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 15.0%/day
Key levels
$4.2352 week high+350.0%
$2.76200 day average+193.6%
$2.33100 day average+147.9%
$1.7350 day average+84.0%
$1.55Swing high (Nov 9)+64.9%
$1.3220 day average+40.4%
$1.00Pivot R1+6.4%
$0.97Pivot+3.2%
$0.94Last close
$0.9352 week low−1.1%
$0.90Pivot S1−4.3%
Indicators
RSI (14)26.48Oversold below 30Oversold
MACD-0.20Below its signal lineBearish
Stochastic6.0Near the bottom of its rangeOversold
ADX (14)39.3Trending down
Williams %R-99.0Oversold below −80, overbought above −20Oversold
CCI (20)-162.9Oversold below −100, overbought above 100Oversold
Rate of change−28.0%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 15.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CABA

What happened before

See how CABA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CABA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CABA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CABAHow many large options trades hit CABA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CABA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲105 buying vs 47 selling
  • ▲Held by funds +13.9 pts
  • ▲Funds holding +22
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding163141+15.6%
In funds' top 1001−100.0%
Held by funds87.5%73.6%+13.9 pts
New / increased35 / 7055 / 500.0%
Reduced / sold out34 / 1320 / 23+9.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CABA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CABA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$296K8 buys · 8 insiders
Sold$00 sales · 0 insiders
Cluster buy: 8 insiders bought $296K between Jan 21 and Jan 21.
2026-01 bought $296KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jan 21Michael GerardGeneral CounselBuy6,600$2.27$15K
Jan 21Mark SimonDirectorBuy11,061$2.28$25K
Jan 21Steven NichtbergerPresident & CEOBuy45,000$2.24$101K
Jan 21Catherine BollardDirectorBuy4,405$2.27$10K
Jan 21Steve GavelChief Commercial OfficerBuy22,170$2.27$50K
Jan 21Shawn TomaselloDirectorBuy22,725$2.21$50K
Every insider buy and sale for CABA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CABA insider trades →

From SEC Form 4 filings by CABA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CABA is in one of them and how their past CABA trades turned out.

CABA in the AI portfolios
Loading…

CABA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CABA in an article yet. Here's the latest on the wider market.

CABA in the news

About Cabaletta Bio

Cabaletta Bio is a biotechnology company based in Philadelphia, Pennsylvania, that develops engineered T cell therapies for people with autoimmune diseases. Its lead candidate, rese-cel, is a CAR T cell treatment designed to deplete B cells, and it is in clinical trials for conditions including myositis, lupus, systemic sclerosis and generalized myasthenia gravis. The company does not yet sell a commercial product, and the patients it aims to serve are people living with these conditions.

Headquarters
Philadelphia, PA